Mesothelin is a specific biomarker of invasive cancer in the Barrett-associated adenocarcinoma progression model: translational implications for diagnosis and therapy.

[1]  F. Sato,et al.  Pituitary tumor-transforming 1 increases cell motility and promotes lymph node metastasis in esophageal squamous cell carcinoma. , 2008, Cancer research.

[2]  S. Skates,et al.  Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. , 2007, Chest.

[3]  Richard G. Moore,et al.  Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment. , 2007, Gynecologic oncology.

[4]  T. Wu,et al.  Control of human mesothelin-expressing tumors by DNA vaccines , 2007, Gene Therapy.

[5]  W. Ma,et al.  A phase 1 study of MORAb-009, a monoclonal antibody against mesothelin in pancreatic cancer, mesothelioma and ovarian adenocarcinoma , 2007 .

[6]  Sailing He,et al.  Imaging pancreatic cancer using surface-functionalized quantum dots. , 2007, The journal of physical chemistry. B.

[7]  Tammy F. Glenn,et al.  Accurate discrimination of pancreatic ductal adenocarcinoma and chronic pancreatitis using multimarker expression data and samples obtained by minimally invasive fine needle aspiration , 2007, International journal of cancer.

[8]  Sailing He,et al.  Quantum rod bioconjugates as targeted probes for confocal and two-photon fluorescence imaging of cancer cells. , 2007, Nano letters.

[9]  T. Wu,et al.  A DNA vaccine encoding a single-chain trimer of HLA-A2 linked to human mesothelin peptide generates anti-tumor effects against human mesothelin-expressing tumors. , 2007, Vaccine.

[10]  Chien-Nan Lee,et al.  Serum mesothelin in epithelial ovarian carcinoma: a new screening marker and prognostic factor. , 2006, Anticancer research.

[11]  S. Batra,et al.  Biomarkers in Diagnosis of pancreatic carcinoma in fine-needle aspirates. , 2006, American journal of clinical pathology.

[12]  N. Sardesai,et al.  Mesothelin Variant 1 Is Released from Tumor Cells as a Diagnostic Marker , 2006, Cancer Epidemiology Biomarkers & Prevention.

[13]  N. Ordóñez,et al.  The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study , 2006, Modern Pathology.

[14]  E. Montgomery,et al.  Overexpression of Claudin Proteins in Esophageal Adenocarcinoma and Its Precursor Lesions , 2006, Applied immunohistochemistry & molecular morphology : AIMM.

[15]  I. Eltoum,et al.  Use of mesothelin as a marker for mesothelial cells in cytologic specimens. , 2006, Seminars in diagnostic pathology.

[16]  C. Mamot,et al.  Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. , 2005, Cancer research.

[17]  M. Lerner,et al.  Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. , 2005, American journal of clinical pathology.

[18]  E. Montgomery,et al.  Concordant Loss of MTAP and p16/CDKN2A Expression in Gastroesophageal Carcinogenesis: Evidence of Homozygous Deletion in Esophageal Noninvasive Precursor Lesions and Therapeutic Implications , 2005, The American journal of surgical pathology.

[19]  R. Hruban,et al.  Expression of novel markers of pancreatic ductal adenocarcinoma in pancreatic nonductal neoplasms: additional evidence of different genetic pathways , 2005, Modern Pathology.

[20]  R. Odze,et al.  Immunohistochemistry Can Help Distinguish Metastatic Pancreatic Adenocarcinomas From Bile Duct Adenomas and Hamartomas of the Liver , 2005, The American journal of surgical pathology.

[21]  E. Montgomery,et al.  CDC2/CDK1 Expression in Esophageal Adenocarcinoma and Precursor Lesions Serves as a Diagnostic and Cancer Progression Marker and Potential Novel Drug Target , 2005, The American journal of surgical pathology.

[22]  R. Hruban,et al.  Mesothelin-specific CD8+ T Cell Responses Provide Evidence of In Vivo Cross-Priming by Antigen-Presenting Cells in Vaccinated Pancreatic Cancer Patients , 2004, The Journal of experimental medicine.

[23]  S. Nie,et al.  In vivo cancer targeting and imaging with semiconductor quantum dots , 2004, Nature Biotechnology.

[24]  Janusz Jankowski,et al.  A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. , 2004, Gastroenterology.

[25]  B. Reid,et al.  Focus on Barrett's esophagus and esophageal adenocarcinoma. , 2004, Cancer cell.

[26]  I. Pastan,et al.  Mesothelin , 2004, Clinical Cancer Research.

[27]  J. Cameron,et al.  Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays. , 2004, Human pathology.

[28]  Christine A Iacobuzio-Donahue,et al.  Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. , 2003, Cancer research.

[29]  Trevor Hastie,et al.  Gene expression patterns in ovarian carcinomas. , 2003, Molecular biology of the cell.

[30]  N. Ordóñez,et al.  Application of Mesothelin Immunostaining in Tumor Diagnosis , 2003, The American journal of surgical pathology.

[31]  D. Faigel,et al.  Novel Markers of Pancreatic Adenocarcinoma in Fine-Needle Aspiration: Mesothelin and Prostate Stem Cell Antigen Labeling Increases Accuracy in Cytologically Borderline Cases , 2003, Applied immunohistochemistry & molecular morphology : AIMM.

[32]  J. Cameron,et al.  Multicomponent Analysis of the Pancreatic Adenocarcinoma Progression Model Using a Pancreatic Intraepithelial Neoplasia Tissue Microarray , 2003, Modern Pathology.

[33]  I. Pastan,et al.  Targeted therapy against human lung cancer in nude mice by high-affinity recombinant antimesothelin single-chain Fv immunotoxin. , 2002, Molecular cancer therapeutics.

[34]  L. Brown,et al.  Epidemiologic trends in esophageal and gastric cancer in the United States. , 2002, Surgical oncology clinics of North America.

[35]  S. Spechler,et al.  Clinical practice. Barrett's Esophagus. , 2002, The New England journal of medicine.

[36]  J. Cameron,et al.  Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  E. Montgomery,et al.  Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study. , 2001, Human pathology.

[38]  G. Riggins,et al.  Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. , 2000, Cancer research.

[39]  Prateek Sharma,et al.  Long-term follow-up of Barrett's high-grade dysplasia , 2000, American Journal of Gastroenterology.

[40]  I. Pastan,et al.  Anti-Tumor Activity of K1-LysPE38QQR, an Immunotoxin Targeting Mesothelin, a Cell-Surface Antigen Overexpressed in Ovarian Cancer and Malignant Mesothelioma , 2000, Journal of immunotherapy.

[41]  D. Antonioli,et al.  Morphology of Barrett's esophagus and Barrett's-associated dysplasia and adenocarcinoma. , 1997, Gastroenterology clinics of North America.

[42]  I. Pastan,et al.  Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[43]  I. Pastan,et al.  Molecular cloning and expression of a cDNA encoding a protein detected by the ki antibody from an ovarian carcinoma (OVCAR‐3) cell line , 1994, International journal of cancer.

[44]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[45]  R. Hruban,et al.  Real-time detection of mesothelin in pancreatic cancer cell line supernatant using an acoustic wave immunosensor. , 2006, Cancer detection and prevention.

[46]  W. Pardridge.  Gene targeting in vivo with pegylated immunoliposomes. , 2003, Methods in enzymology.